CN101829101A - Application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B - Google Patents
Application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B Download PDFInfo
- Publication number
- CN101829101A CN101829101A CN 201010181721 CN201010181721A CN101829101A CN 101829101 A CN101829101 A CN 101829101A CN 201010181721 CN201010181721 CN 201010181721 CN 201010181721 A CN201010181721 A CN 201010181721A CN 101829101 A CN101829101 A CN 101829101A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- hbsag
- virus
- hbv
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B, in particular to application of silybin ester flavonolignan substituted by ethoxycarbonyl methyl on the ring A or a pharmaceutically acceptable salt thereof for preparing medicaments for reducing the hepatitis B virus surface antigen (HBsAg), suppressing the HBV (Hepatitis B Virus) DNA replication and treating HBV infection diseases. The flavonolignan has quite obvious activity on suppressing the HBsAg, and in the presence of a concentration of 100 micrograms/milliliter, the intensity of the flavonolignan for clearing away the HBsAG exceeds that of alpha-interferon which is a positive control medicament by 3.3 times. Meanwhile, in the presence of a concentration of 20 micrograms/milliliter, suppression ratio of the compound to the HBV DNA is close to 60 percent. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for treating the HBV infection diseases.
Description
Technical field
The present invention relates to medical technical field, particularly, the present invention relates to the methyl substituted silybin ester flavonolignan of ethoxycarbonyl on a kind of A ring or its officinal salt be used to prepare reduce hepatitis B virus surface antigen HBsAg medicine, suppress the HBV dna replication dna, the purposes of the hepatitis b virus infected disease medicament of treatment, this flavanolignan has and suppresses the HBsAg activity very significantly, and it is removed HBsAg intensity and surpasses 3.3 times of positive control medicines (alpha-interferons of 10000 units per ml) under 100 mcg/ml concentration; Simultaneously, this chemical compound demonstrates HBV DNA and is close to 60% suppression ratio when 20 mcg/ml concentration.Above pharmacodynamic result show this flavanolignan or its officinal salt can expect be used to prepare reduce hepatitis B virus surface antigen, suppress the HBV dna replication dna, the purposes of the hepatitis b virus infected disease medicament of treatment.
Background technology
Hepatitis B (hepatitis B) is the infectious disease that is caused by hepatitis b virus hbv.HBV is a member of Hepadnaviridae hepadnaviridae, and it is shaped as the spheroidal particle of diameter 42 nanometers.HBV is peculiar virus, and less being infectious in other animal has only in human body or primate chimpanzee body and just can duplicate.This virus is propagated by hepatitis B virus carriers and hepatitis B patients'blood, saliva, seminal fluid, vaginal secretions, has chronic carrier state.Hepatitis B is widely current in China, and because of it is divided in vertical transmission, horizontal transmission, the family propagation, iatrogenic infection and multiple mode such as spread through sex intercourse, to crowd infection rate's height, infection rate reaches more than 35% in certain areas.According to interrelated data, hepatitis detects male patient and has reached 1.89 hundred million, and the number (carrier) nearly 400,000,000 of should not going to a doctor is one of the most serious infectious disease of current harm people ' s health.Hepatitis B clinical manifestation variation easily develops into chronic hepatitis B (CHB) and liver cirrhosis, and a few patients can change primary hepatocarcinoma into.
Hepatitis B surface antigen (HBsAg) is the coat protein of hepatitis B virus, and the HBsAg positive is a goldstandard of judging that HBV infects.The HBsAg positive but do not have the hepatitis symptom person of appearance and become HBV virus carrier.The HBsAg titre is big more, and it is just big more that it merges the active probability that raises of hepatitis B virus core antigen HBeAg, the HBV DNA positive and DNA polymerase, thereby infectiousness is strong more.In like manner, suppress the secretion of HBsAg and duplicate and also be an important target in the research and development anti-hepatic-B virus medicine and detect target.Report: hepatitis B HBsAg such as the refined cloud of the Wu of Beijing Ditan Hospital remove and there is certain dependency in hepatitis B closed loop covalency DNA (cccDNA), and removing HBsAg is the significantly reduced sign of cccDNA level.2002, deliver the researcher of result of study at " New England Journal of Medicine " and think: for CHB patient, remove as obtain HBsAg before liver cirrhosis, then its liver cirrhosis and hepatocarcinoma incidence rate will reduce by 60 times.All HBsAg serum is removed in the guide of the AASLD of U.S. hepatopathy research association, the Asia-Pacific liver APASL of research association and the EASL of EASL as one of treatment terminal point determining standard.
According to European liver EASD in 2008 annual meeting: Polyethylene Glycol Intederon Alpha-2a treatment CHB patient 48 week back drug withdrawals, followed up a case by regular visits to 1,2,3,4 year, its HBsAg clearance rate is respectively 3%, 6%, 8% and 11%, and 1,2,3,4 to be only be 0%, 0%, 0% and 3% after drug withdrawal to the HBsAg clearance rate with the lamivudine person separately.Thereby this interferon is considered to treat the negative CHB patient's optimal treatment selection of HBeAg.As seen find that the medicine that can efficiently remove HBsAg has important social and economic benefit.
At present, the medication to hepatitis B patient mainly is divided into several big classes such as the liver protecting and ALT lowering, antiviral, anti-hepatic fibrosis and adjusting immunity.The research that still is the antiviral treatment aspect that made progress in the last few years.Antiviral is a basic method, and the liver protecting and ALT lowering is an auxiliary treatment, takes stopgap measures and rarely seen effecting a permanent cure more.Yet, can only reach for viral hepatitis B therapeutic scheme clinically at present and suppress hbv replication and secondary infection, main medicine is still nucleoside medicine such as lamivudine (3-TC), Entecavir, adefovirdipivoxil (ADV), Sebivo etc., is in the interim emtricitabine of clinical trial, tenofovir, clevuding etc. in addition.In China, lamivudine has become the medical insurance medication, is applied to large quantities of HBV patients.Nucleoside medicine part advantage is: the bioavailability height, and oral safer.Yet, though their disease controlling, fetch long prices first effectively; Second life-time service all drug resistance can occur, and the bounce-back in various degree that occurs HBV DNA, ALT and liver histological after the drug withdrawal; The 3rd, the comparatively tangible well-known ill effect that the life-time service nucleoside medicine occurs, for example kidney injury, baby's teratogenesis etc.Headache is the most: virus is drug-fast cure rate to occur greatly reducing, because nucleoside medicine is reversible to virus replication, thus to most of patient if desire to reach greatest treatment efficacy, the course of treatment must be more than 1 year, so its drug resistance occurs thereupon, does not just reach the effect of expection.Nucleoside medicine be difficult in addition remove cccDNA, treatment after 1 year HBsAg be difficult to weak points such as cloudy commentaries on classics.
The biological engineering class antiviral drugs that interferon (α, beta-interferon) and recombinant interferon class etc. derive from human leukocyte becomes research and treatment CHB focus medicine in the recent period, and it has antiviral and immunomodulating dual function.Thereby it both can suppress virus replication by antivirus action and alleviate the liver cell inflammatory reaction, reduces hepatocellular damage, plays and improves patients clinical symptom and liver physiological function thereby delay PD; Again can the enhance immunity effect, by the effect of natural killer cell in the intensive aspect and helper T lymphocyte, especially can promote killer T cell to go to kill and wound by virus infected cell, therefore play antivirus action indirectly.The HBsAg serology conversion that interferon therapy CHB patient obtains is more more lasting than lamivudine, and " digestive tract " magazine the next item up studies show that in 2003: 3 years relapse rates of interferon therapy group HBsAg significantly are lower than the lamivudine group; And long-acting interferon can use weekly once, and is comparatively convenient.Therefore, interferon day by day becomes one of choice drug that is used for the treatment of chronic viral hepatitis B virus clinically, but its side effect and untoward reaction report are more, total effective rate is not high, cost an arm and a leg, patient economy burden is big, thereby causes and be difficult to clinically be extensive use of, and the decompensated cirrhosis patient is not suitable for using.
Along with the research of hepatopathy, developed the analysis of standardized HBV DNA in recent years, advanced understanding greatly the hepatitis B patient state of an illness.The quantitative analysis of HBV DNA can be predicted the seriousness and the prognosis thereof of hepatitis B, because HBV DNA lasting masculin (promptly continuing viremia) makes the hepatitis B disease progression easily and increases the weight of; High hepatitis B virus (HBV DNA) content promotes the formation of liver cirrhosis easily; The lasting existence of HBV DNA is that the high risk factor, particularly viral level of hepatocarcinoma (HCC) generation is higher, the course of disease is long, older or merge other liver patient; The HBV DNA that continues high concentration exists, and the mortality rate that can cause losing compensatory liver cirrhosis and constitutional liver serious symptom obviously increases.Simultaneously must recognize that the relation of HBV dna level and liver histological is extremely close: bibliographical information is through antiviral therapy, and the improvement of hepatic fibrosis and elimination are obviously; Recent international hepatopathy meeting report, potent and low chemical sproof antiviral therapy along with the reduction of HBV DNA with turn out cloudy, in various degree reverse can occur and observe liver cirrhosis, and therefore present opinion liver cirrhosis also should carry out antiviral therapy.
Therefore, the application of HBV DNA index in antiviral therapy also plays a part very important: the level of HBV DNA is the important indicator whether the decision chronic hepatitis B needs antiviral therapy; Make the difference treatment standard and the requirement of the HBeAg positive or HBeAg feminine gender respectively according to the different situations of HBV DNA; In antiviral therapy, according to the therapeutic response of HBVDNA, judge whether that virusology replys in early days and then determine the strategy of long-term prescription to reply with the virusology that obtains persistence, reach and continue the purpose that virus suppresses; According to the virological situation of replying of HBVDNA, create serological switching foundation of HBeAg and condition, to reach its good middle therapeutic goal; Continue the inhibition situation according to HBV DNA and strive for that virus continues feminine gender, to strive for reaching the final therapeutic goal of antiviral; Continue to be suppressed fully according to HBV DNA, also demonstrated improvement in various degree and the disappearance of cccDNA; In antiviral therapy, assess and prevent the risk of caused virus variation of antiviral drugs and drug resistance generation with the variation of HBV DNA; In case when virus variation or drug resistance took place, the variation of HBV DNA was unique signal at first and diagnosis basis, also be treatment drug resistance and guidance and the foundation that changes therapeutic strategy.In sum, the inhibition degree of HBV DNA there is new important meaning in the further diagnosis of hepatitis B and treatment,, assessment hepatitis B prognosis and drug resistance danger is all had bigger directive function the observation of curative effect.
By above-mentioned factor as can be known: the basic link of another one that the inhibition hepatitis B virus is bred in vivo is to suppress duplicating of HBV DNA.The reduction of HBV dna level or be lower than detection level be the check antiviral drugs other one JINYAOSHI.So, Asia-Pacific liver EASD and European liver EASD all with the HBV DNA detection less than as one of hepatitis B virus patient treatment terminal point.Also tested compounds is considered as one of the test event that must finish for the inhibition strength of HBV DNA in China's new drug development guide.Why lamivudine can become first-selected nucleoside medicine is because it has the activity of potent inhibition HBV dna replication dna.Therefore can suppress the novelty medicine that chemical compound that the HBV dna replication dna can suppress HBsAg again will more promise to be the treatment hepatitis B patient.
Mandatory declaration be: the present antiviral drugs of the using inhibitor of virus replication just in fact, directly kill virus and break virus body, otherwise will damage host cell.These antiviral drugs (mostly being nucleoside medicine) also exist above-mentioned toxic and side effects greatly, easily to cause after viral gene sudden change, the drug withdrawal shortcomings such as easily knock-on, so the development of new antiviral drugs is the task of top priority in current medicament research and development field.It all has extremely important social meaning and economic implications for a large amount of hepatitis B patient and virus carrier, the control sources of infection etc. of treatment China.So new non-nucleoside hepatitis B virus inhibitor and this type of lead compound that can reduce HBsAg or inhibition HBV dna replication dna of discovery has very big guiding significance from the natural drug of national folk life-time service, and vast development prospect is arranged.
Based on this purpose, the inventor once finished the patent and the article of multinomial anti-hepatitis virus natural product and structure of modification derivant thereof in the past, having found multiple inhibition hepatitis B virus surface antigen HBsAg or hepatitis B virus e antigen HBeAg activity, suppress the chemical compound of HBV dna replication dna, is feasible [referring to " medical usage of a class mapping eucalyptus globulus alkanol type sesquiterpene for inhibiting hepatitis virus " (Zhao Yu, Liu Guangming, Yu Rongmin, Li Haibo etc. thereby explanation filters out the novelty medicine that can reduce HBsAg, control hepatitis B virus infection from natural product and synthesis of derivatives thereof; ZL 200610053827.4); " medical usages of 2 beta-hydroxy Ilicis Purpureae acid for inhibiting hepatitis B virus " (Lee school Kun, Zhao Yu, Huang Kexin, Li Haibo etc.; ZL 200610053749.8); " 2 α, the medical usage of 3 beta-dihydroxies-5,11 (13)-diene eucalyptus globulus alkane-12-acid for inhibiting hepatitis B virus " (Zhao Yu, Zhang Li and, Dong Sun Han, Li Haibo etc.; ZL 200610053601.4); The purposes and the pharmaceutical composition thereof of hepatitis B virus " the eremophilane lactone suppress " (Zhao Yu, Li Haibo, Yang Leixiang, girth are new etc.; ZL 03153691.3); " a kind of Eremophilone lactones acid natural product and application thereof " (Zhao Yu, girth new, Shi Shuyun, Wang Xiaoyu etc.; ZL200610053575.5); " a kind of eudesmane type sesquiterpenes acid and uses thereof " (Zhao Yu, Liu Guangming, Li Haibo, Wu Xiumei etc.; ZL 200610053579.3); " purposes of laggera plant abstract in inhibiting herpes simplex virus and hepatitis B virus " (Zhao Yu, girth new, Yu Rongmin, Bai Hua; CN 1989989A); " medical usage of 1 β-oxo-5,11 (13)-diene eucalyptus globulus alkane-12-acid for inhibiting hepatitis B virus " (Zhao Yu, Lee school Kun, Huang Kexin, Li Haibo etc.; CN1927197A); " medical usage of 1 beta-hydroxy Ilicis Purpureae acid for inhibiting hepatitis B virus " (Zhao Yu, Lee school Kun, Huang Kexin, Wu Xiumei etc.; CN 1935131A); " medical usage of acid of mapping eremophilane and inhibition hepatitis B surface antigen thereof " (Huang Kexin, Lee school Kun, Wang Xiaoyu, Zhao Yu etc.; CN 101239054); " 1-oxygen-substituted benzene formyl quinic acid chemical compound and inhibition hepatitis B virus purposes thereof " (Lee school Kun, Hu Lihong, Wu Xiumei, Zhao Yu etc.; CN 101293836); Inhibition HBsAg that the inventor has delivered and HBV DNA isoreactivity article are referring to " In VitroAntiviral Activity of Three Enantiomeric Sesquiterpene Lactones fromSenecio Species Against Hepatitis B Virus ", Haibo Li (Li Haibo), Changxin Zhou (girth is new), Xiumei Wu (Wu Xiumei), Yu Zhao* (Zhao Yu) etc., Antiviral Chemistry﹠amp; Chemotherapy, 2005,16,277-282; " Evaluation of Antiviral Activity of Compounds Isolated fromRanunculus sieboldii Miq.and Ranunculus sceleratus L ", Haibo Li (Li Haibo), Changxin Zhou (girth is new), Xiumei Wu (Wu Xiumei), Yu Zhao* (Zhao Yu) etc., Planta Medica, 2005,71 (12), 1128-1133; " Application ofhigh-speed counter-current chromatography for the isolation of antiviraleremophilenolides from Ligularia atroviolacea ", Shi, Shu-Yun (Shi Shuyun), Hai-Bo (Li Haibo), Zhao, Yu (Zhao Yu) etc., Biomedical Chromatography, 2008,22 (9), 985-991; " Purification and identification of antiviralcomponents from Laggera pterodonta by high-speed counter-currentchromatography ", Shuyun Shi (Shi Shuyun), Yu Zhao (Zhao Yu) etc., Journalof Chromatography B, 2007,859,119-124].Undoubtedly, continuing to seek the lead compound that can remove HBsAg or inhibition HBV dna replication dna from natural product and structure of modification derivant thereof is that very therefore being necessary property is also classified as one of great special project of new drug development by the Ministry of Science and Technology with urgent.
In above-mentioned treatment CHB medicine, also having a class is to protect the liver the class medicine, its clinical a large amount of uses be typically silymarin in the seed that is present in the feverfew Herba Silybi mariani.Herba Silybi mariani is extensive use clinically, its commodity Legalon by name on market
TMGrand or the Flavobion of sharp liver
TM, its representative compounds surely belongs to flavanolignan's silibinin.Flavone lignin compound belongs to weedtree quality class, is a class natural product of and a part flavone be combined into plain by a part phenylpropyl alcohol.Silibinin content is maximum in the Herba Silybi mariani, and activity is also the highest.This medicine effect mainly contain following some: (one) free radical resisting activity: silymarin has protective effect for the hepatic injury that is caused by carbon tetrachloride, galactosamine, alcohols and other hepatotoxin.People such as nineteen ninety Lotteron have reported in the Mouse Liver microsome, silymarin can reduce external lipid peroxidation that is caused by the carbon tetrachloride metabolism and the peroxidation that is caused separately by reduced coenzyme, and these show that all silymarin is the chain interruption antioxidant or is free radical scavenger.(2) protection liver plasma membrane: keep flowability of cell membranes by the anti peroxidation of lipid reaction, the protection liver plasma membrane.Can also block combining of special receptor on mycotoxin phalloidine and α-amanitin etc. and the hepatocyte, suppress it, interrupt its liver sausage circulation, thereby the enhance hepatocyte film be for the resistance of multiple damage factor hepatocellular attack and transmembrane transport.(3) promote hepatocellular reparation and regeneration: silibinin can combine with estradiol receptor after entering cell, and make it to activate, activated receptors can enhance hepatocyte nuclear RNA polymerase 1 activity, rna transcription is strengthened, promote enzyme and proteinic synthetic, and promote the synthetic of DNA indirectly, help hepatocellular reparation and regeneration.(4) antitumor action: various active oxygens can form 8-hydroxyl guanine by the oxidation guanine, cause DNA damage, and then cause tumor, and silibinin has also shown the effect of prevention and treatment tumor as an effective free radical resisting material.This medical instrument of the clinical trial certificate of three more than ten years has definite curative effect and hypotoxicity (to consult Flora, K. etc., Am.J.Gastroenterol, 1998,93,139-143; Saller, R. etc., Drugs, 2001,61 (14), 2035-2063;
, R. etc., Curr.Med.Chem.2007,14,315-338;
, Z. etc., Phytother.Res.2003,17,524-530;
, R. etc., Bioorg.Med.Chem.2004,12,5677-5687; Varga, Z. etc.; Phytothe.Res.2001,15,608-612.Singh, R.P. etc., Curr.CancerDrug Tar.2004,4,1-11).Therefore, the flavone lignin chemical compound that with the silibinin is representative has caused increasing concern, in the period of 2006-2009, prepare and a plurality of serial silibinin analog derivative reported also has obvious antioxidation activity (Yang Leixiang, Zhao Yu etc. as the inventor, " Design; synthesis andexamination of neuron protective properties of alkenylated and amidateddehydro-silybin derivatives ", Journal of Medicinal Chemistry, 2009,52 (23), 7732-7752; Wang Feng, Zhao Yu etc., " Preparation of C-23 esterified silybinderivatives and evaluation of their lipid peroxidation inhibitory and DNAprotective properties ", Bioorganic﹠amp; Medicinal Chemistry, 2009,17 (17), 6380-6389; Yang Leixiang, Zhao Yu etc., " Synthesis and Antioxidant PropertiesEvaluation of Novel Silybin Analogues ", Journal of Enzyme Inhibitionand Medicinal Chemistry, 2006,21 (4), 399-404; Or the like).In the above-mentioned article of inventor report, flavanolignan's compounds of the A ring of a plurality of series that design and synthesize out through the inventor, B ring, E ring, 23 replacements all demonstrates the activity of the potent DPPH of catching free radical and ultra-oxygen anion free radical, antioxidant activity and protection PC12 cell activity.But apparent: above-mentioned research only concentrates on antioxidation and the cytoprotection of studying the silibinin flavonolignan.
(2006) in the recent period, Xie Jun has reported that use in conjunction has the interferon of antiviral and immunomodulating dual function and the silibinin phosphatide complexes of hepatoprotective is treated the result of chronic viral hepatitis B, it is more obvious than using the interferon effect separately to find that drug combination reduces ALT, AST value in patient's body, illustrates that the silibinin phosphatide complexes can strengthen the effect of the treatment chronic viral hepatitis B of interferon.But similarly therapeutic scheme is still flavanolignans such as silibinin as adjuvant drug, and mainly is to be used to protect liver plasma membrane but not directly to implement antivirus action with it.(left side is state-run for the state-run grade in a left side, Liu Shuling, Xu Guili, world Chinese digests magazine, 2006 14 13 phases of volume, the 1241-1246 page or leaf) summarized the active progress of the external anti-HBV of medicinal plants composition over nearly 20 years, the multiple natural product of touching upon in the literary composition, do not report that wherein any flavanolignan compounds has the active relative recording of anti-HBV, especially silibinin class natural product and derivant thereof, domestic almost nobody relates to, and only by inventor team it has been carried out structure of modification and the anti-HBV activity research that forefathers do not add attention.One of our purpose is: flavanolignan's lead compound of wish finding to reduce HBsAg or suppressing the HBV dna replication dna has the novelty medicine that can remove HBsAg, suppress the treatment CHB that HBVDNA duplicates thereby it is developed further into.
Though be the antioxidation curative effect that flavanolignan's chemical compound of representative has the above with the silibinin, yet it appears in the newspapers less relatively in the document of antiviral therapy aspect, the compounds for treating DNA of flavanolignan viroid infection especially its new purposes that is used for anti-hepatitis virus aspect (comprise and suppress HBsAg or suppress the HBV dna replication dna) is effectively developed as yet, so seek the reactive compound in anti-hepatitis virus field from flavanolignan, that is being about to flavanolignan's structure of modification, to make it have anti-DNA viroid activity be a brand-new field.From the lead compound challenge that forefathers did not attempt especially of wherein finding to suppress HBsAg or suppressing the HBV dna replication dna.In order to explore this field; our design has also prepared and silibinin structure a kind of new flavanolignan's derivant of difference to some extent; also promptly on encircling 7, the A of former silibinin connects an ethoxycarbonyl ylmethyl; prolong the replacement length of 7 former phenolic hydroxyl group modules of A ring, introduced a plurality of new hydrogen bond receptors or donor simultaneously.So design can generate the plain flavanone alcohol compound (also being the novel flavanolignan of class chemical compound) of a class novel wooden that the new spatial structure is different from silibinin, in the hope of finding the activity and even the lead compound of unusual inhibition hepatitis B HBsAg or inhibition HBV dna replication dna, finish the present invention in view of the above.
Summary of the invention
The purpose of this invention is to provide the methyl substituted silybin ester flavonolignan of ethoxycarbonyl on the A ring shown in the formula (1) or its officinal salt and be used for that preparation reduces HBsAg, suppresses the HBV dna replication dna, the new purposes of treatment hepatitis B medicine.
The name of formula (1) chemical compound is called: (±)-2,3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5 ,-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
The present invention also provides the method for ethoxycarbonyl ylmethyl silybin esters flavonol Lignanoids compounds on the A ring shown in a kind of preparation formula (1), it is characterized in that: silibinin gets with halogenated acetic acids ethyl ester prepared in reaction under the potassium iodide catalysis of alkali and trace; Wherein alkali is inorganic base or organic base, preferred inorganic base; The preferred ethyl chloroacetate of halogenated acetic acids ethyl ester.
Another object of the present invention has provided and a kind ofly has been used to reduce HBsAg or suppresses the pharmaceutical composition that HBVDNA duplicated, treated hepatitis B, it is characterized by by containing the mixture that (1) chemical compound of the formula as active component for the treatment of effective dose or its officinal salt and pharmaceutically acceptable auxiliaries are formed.Its pharmaceutical dosage form can be that tablet, capsule, injection, aerosol, suppository, membrane, drop pill, paster agent, subcutaneous planting bury agent, externally-applied liniment, oral liquid or ointment, can also adopt the known controlled release of modern pharmaceutical circle or slow release formulation or nanometer formulation.
The methyl substituted silibinin ester compounds of ethoxycarbonyl (1) is compared with natural flavone Lignanoids compounds silibinin on the A ring of the present invention, feature with differentiation on many structures and the physico-chemical property comprises that speciality such as its hydrophobicity, armaticity, Gibbs free energy, hydrogen bond receptor, electrical, intermolecular Van der Waals force and 3D conformation, direction of extension, molecule center of gravity, electrical distribution center all have obviously different with silibinin; And chemical compound (1) molecular weight ratio silibinin has increased 86 mass units.Above-mentioned feature has all determined the three-dimensional conformation of chemical compound shown in the formula (1) all may produce bigger difference with the ligand-receptor that the 3d space structure of HBsAg or HBV DNA combines in conjunction with complex form and combination, its binding site and binding pattern, it all can produce bigger change in conjunction with free energy etc., thereby may suppress HBsAg or suppress aspect the HBV dna replication dna beyond thought effect arranged.
We have tested the growth inhibited effect of this chemical compound to the HepG2.2.15 cell, have tested it simultaneously to B-mode HBsAg of HepG2.2.15 emiocytosis and to the inhibition activity of HBV dna replication dna.Result of the test is found: among the present invention on the synthetic A ring that obtains the methyl substituted silybin ester of ethoxycarbonyl be (±)-2,3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5,-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone has significant inhibition activity to the B-mode HBsAg of HepG2.2.15 emiocytosis, and it removes HBsAg intensity above 3.3 times of positive control medicines (alpha-interferons of 10000 units per ml) under 100 mcg/ml concentration; Simultaneously, this chemical compound demonstrates HBV DNA and is close to 60% suppression ratio when 20 mcg/ml concentration.More than all formula (1) chemical compound beyond thought anti-HBV effect is arranged, thereby can expect that it can be used as the active lead compound that reduces hepatitis B HBsAg or suppress HBV dna replication dna, treatment hepatitis B and continues exploitation.
Through the detailed Literature Consult of the inventor, up to the present, still there is not report about this compounds for treating hepatitis B virus infection disease and preparation anti-hepatic-B virus medicine.Flavanolignan's formula (1) chemical compound all belongs to beyond thought discovery for HBsAg and the potent inhibition of HBV DNA, and definite originality is arranged, and finishes the present invention in view of the above.In sum, uniqueness on our synthetic this silybin ester flavonolignan existing structure, the novelty that the research of antivirus action aspect is arranged again, and in anti-hepatitis B activity test, found the activity of uncommon inhibition HBsAg to be expected to become the lead compound that reduces HBsAg or suppress HBV dna replication dna, treatment CHB.
Usefulness of the present invention is: the methyl substituted silybin ester flavonolignan of ethoxycarbonyl has the effect that reduces hepatitis B HBsAg, suppresses the HBV dna replication dna on the A ring shown in the discoverable type (1) first, and the patent medicine potentiality aspect control hepatitis B virus infection disease.The original new drug that becomes treatment hepatitis B virus original new drug, exploitation reduction HBsAg or inhibition HBV dna replication dna for exploitation provides new material base.Have potential huge social benefit and economic benefit.The present invention's characteristics again is: the present invention's synthetic starting material convenient sources, and synthetic convenient.Its preparation method is simple, and raw material sources conveniently are easy to get, and cost is low, pollutes for a short time, is beneficial to the large-scale production under the energy-saving and emission-reduction condition.Industrialization prospect is very clear and definite.
The specific embodiment
The inventor is simply synthetic by multistep; and obtain the secretion that this can potent inhibition hepatitis B HBsAg by the chromatography means and can effectively suppress the methyl substituted silybin ester flavonolignan of ethoxycarbonyl class reactive compound on the active A ring of HBV dna replication dna, derive its chemical constitution through integration analysis such as mass spectrum and NMR (Nuclear Magnetic Resonance) spectrum again.The inventor finds, formula (1) chemical compound does not have obvious inhibitory action to the growth of HepG2.2.15 cell, and secretion and the duplicating of HBV DNA of the hepatitis B HBsAg of HepG2.2.15 emiocytosis had significant inhibitory effect, point out this chemical compound to have drug safety, potent reduction HBsAg, and suppress HBV dna replication dna characteristics of high efficiency.Therefore, according to the inventor's research, the flavanolignan's chemical compound shown in the designed and synthetic formula of inventor (1) can be used to prepare the medicine of treatment hepatitis B virus infection disease and be used for the treatment of the hepatitis B virus infection disease.
In order to understand essence of the present invention better, use the preparation of formula (1) chemical compound below respectively and, its new purposes in pharmaceutical field is described to the HepG2.2.15 cell growth inhibition and to the result of the inhibitory action test of the HBsAg of HepG2.2.15 emiocytosis and HBV dna replication dna.Embodiment has provided partial synthesis, the structure of formula (1) chemical compound and has identified and activity data that wherein OEt is meant ethyoxyl.Mandatory declaration, embodiments of the invention are to be used to illustrate the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.
Embodiment 1:Formula (1) chemical compound (±)-2,3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5, the preparation of-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone
1.1 instrument and reagent:
Ultraviolet spectra is measured with Shimadzu UV-240 ultraviolet spectrophotometer; Proton nmr spectra
1H-NMR measures (tetramethylsilane ether TMS is interior mark) by INOVA type NMR spectrometer with superconducting magnet (VARIAN INOVA-400MHz); Electrospray Mass Spectrometry ESI-MS is measured by BrukerEsquire 3000+ mass spectrograph, and column chromatography is produced by Haiyang Chemical Plant, Qingdao with silica GF254 (10-40 order) with silica gel (100-200,200-300 and 300-400 order) and thin layer chromatography; Agents useful for same is analytical pure, and wherein the petroleum ether boiling range is 60-90 ℃; Thin layer preparative chromatography (PTLC) the aluminium foil silica gel plate of Merck company; Column chromatography adopts Sweden Amersham Pharmacia Biotech AB company product with polydextran gel Sephadex LH-20; Reverse phase silica gel RP-18 adopts the Chromatorex product of Japanese Fuji Silysia Chemical company; MCI is a Mitsubishi chemical company product, and thin plate (TLC) detects the uviol lamp with 254nm and 365nm; Developer iodine vapor, 10% sulphuric acid-ethanol and phosphorus molybdenum acid solution.
1.2 the preparation of chemical compound (1):
In exsiccant reaction bulb, add 0.482 gram silibinin (available from Liaoning Panjin lucky chance pharmaceutcal corporation, Ltd; HPLC detects purity 98%); 0.11 gram potassium carbonate; 6 milligrams of potassium iodide place three-necked bottle; argon shield adds 10 milliliters of DMF down and stirred 10 minutes; add 0.11 milliliter of ethyl chloroacetate, stirred 4 hours under the room temperature.Distilling under reduced pressure removes desolvates, and the residue dissolving is after silica gel column chromatography, chloroform-methanol (100: 1-3: 1) gradient elution, buff powder 0.47 gram.R
f(chloroform: ethyl acetate: formic acid=25: 1: 0.25)=0.26;
1HNMR (400MHz, deuterated dimethyl sulfoxide): δ 1.29 (triplet, J=7.2Hz, 3H, OCH
2CH
3), 3.76 (unimodal, 3H, OCH
3), 3.98 (multiplet, 1H, H-23a), 4.06 (multiplet, 1H, H-23b), 4.23 (multiplet, 1H, H-10), 4.26 (q, J=7.2Hz, 2H, CH
2CH
3), 4.36 (1H, H-3), 4.82 (unimodal, 2H, H-1 ', OCH
2CO), 4.89 (bimodal, J=7.6Hz, 1H, H-11), 6.05 (unimodal, 1H, H-6), 6.21 (unimodal, 1H, H-8), 6.82～8.05 (multiplet, 6H, Ar-H), 12.24 (unimodal, 1H, 5-OH); Electrospray Mass Spectrometry ESI-MS:m/z 569[M+H]
+
Embodiment 2:Chemical compound (1) is to the inhibitory action of the hbs antigen (HBsAg) of HepG2.2.15 emiocytosis
2.1 cell culture:
In containing 10% inactivated fetal bovine serum, 100U/ ml penicillin and 100U/ milliliter streptomycin in the DMEM culture medium of 100 mcg/ml G418, are put 37 ℃, 5%CO with the HepG2.2.15 cell culture
2, cultivate in the incubator of 100% relative humidity.
Measure the inhibitory action of formula (1) chemical compound 2.2 adopt mtt assay to the growth of HepG2.2.15 cell:
The take the logarithm HepG2.2.15 cell of trophophase becomes 1 * 10 with culture medium with cell dilution
5Individual/milliliter, be inoculated in 96 porocyte culture plates, every hole 100 microlitres, at 37 ℃, 5%CO
2, cultivate the chemical compound (1) that adds after 24 hours with the culture medium dilution in the incubator of 100% relative humidity, concentration is respectively 1000 mcg/ml, 200 mcg/ml, 40 mcg/ml and 8 mcg/ml, every hole 200 microlitres, each concentration is established three multiple holes, places 37 ℃, 5%CO
2, cultivate in the incubator of 100% relative humidity, to cultivate after 72 hours, every hole adds MTT reagent 10 microlitres, continues to cultivate 4 hours, discards culture medium, and every hole adds the DMSO200 microlitre, with agitator vibration 20 minutes, measures the OD value with microplate reader under the 570nm wavelength.With the culture hole that only adds culture medium is control wells.Suppression ratio (%)=(control wells OD value-experimental group OD value)/control wells OD value * 100%.The experiment triplicate.
Measure the inhibitory action of chemical compound to hbs antigen (HBsAg): the HepG2.2.15 cell of the trophophase of taking the logarithm becomes 1 * 10 with culture medium with cell dilution
5/ milliliter is inoculated in 96 porocyte culture plates, 100 milliliters in every hole, and at 37 ℃, 5%CO
2, cultivate the sample that adds after 24 hours with the culture medium dilution in the incubator of 100% relative humidity, concentration is respectively 100,20 and 4 mcg/ml, every hole 200 microlitres, each concentration is established three multiple holes, places 37 ℃, 5%CO
2, cultivate in the incubator of 100% relative humidity, changed the culture medium that contains the same concentrations sample in per 4 days, with the culture medium equal-volume mixing that swaps out of the same concentration of same sample, as testing sample.With HBsAg concentration in the ELISA kit measurement culture medium, represent with P/N; With the positive contrast 1 of lamivudine (3-TC) (test concentrations is 100,20 and 4 mcg/ml); With the positive contrast 2 of alpha-interferon (test concentrations is 10000 units, 5000 and 1000 units per ml).
2.3 experimental result:
Experimental result is as shown in table 1, and formula (1) chemical compound has the effect of significant inhibition hbs antigen (HBsAg).Its growth to the HepG2.2.15 cell does not have obvious inhibitory action, is higher than lamivudine and alpha-interferon but the HBsAg of HepG2.2.15 emiocytosis was suppressed activity under the high dose the 8th day the time.
Table 1. sample in the time of the 8th day to the excretory hbs antigen suppression ratio of HepG2.2.15
This embodiment presentation of results: the flavanolignan's chemical compound (±)-2 shown in the formula (1), 3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5,-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone has significant inhibitory effect to the hbs antigen (HBsAg) of HepG2.2.15 emiocytosis, it suppresses activity to HBsAg when higher concentration (100 mcg/ml) be 4.6 times of lamivudines, and suppress active high more than 2.3 times than corresponding HBsAg under the highest test concentrations 10000 units per ml concentration of alpha-interferon; As seen there is very strong inhibition viral secretory surface antigen activity in this flavanolignan.
It is the state of approaching healing clinically that HBsAg removes, and for hepatitis B patient, its HBsAg removes becomes very valuable CHB treatment terminal point.Thereby the flavanolignan's chemical compound shown in the formula (1) can be expected and developed into the medicine that reduces hbs antigen, control Type B viral hepatitis symptom.
Embodiment 3:The inhibitory action that formula (1) chemical compound duplicates the hepatitis B virus DNA (deoxyribonucleic acid) (HBV DNA) of HepG2.2.15 emiocytosis
3.1 cell culture: method is with embodiment 2.
Measure the inhibitory action of the flavanolignan's chemical compound shown in the formula (1) to the growth of HepG2.2.15 cell 3.2 adopt mtt assay: method is with embodiment 2.
3.3 the inhibitory action that the flavanolignan's chemical compound shown in the mensuration formula (1) duplicates hepatitis B virus DNA (deoxyribonucleic acid) (HBV DNA): the HepG2.2.15 cell of the trophophase of taking the logarithm becomes 1 * 10 with culture medium with cell dilution
5Individual/milliliter, be inoculated in 96 porocyte culture plates, every hole 100 microlitres, at 37 ℃, 5%CO
2, cultivate the flavanolignan's chemical compound that adds after 24 hours with shown in the formula (1) of culture medium dilution in the incubator of 100% relative humidity, concentration is respectively 100 mcg/ml, 20 mcg/ml and 4 mcg/ml, every hole 200 microlitres, each concentration is established three multiple holes, place 37 ℃, 5%CO
2, cultivate in the incubator of 100% relative humidity, changed the culture medium that contains the same concentrations sample in per 4 days, with the culture medium equal-volume mixing that swaps out of the same concentration of same sample, as testing sample.Measure HBV DNA concentration in the culture medium with HBV DNA quantitative PCR kit in the time of the 8th day.(annotate: the lamivudine test concentrations is 100 mcg/ml with the positive contrast 1 of lamivudine (3-TC), 20 mcg/ml and 4 mcg/ml), with the positive contrast 2 of alpha-interferon (annotate: the alpha-interferon test concentrations is 10000 units per ml, 5000 units per ml and 1000 units per ml).
3.4 experimental result: experimental result is as shown in table 2, and flavanolignan's formula (1) chemical compound has the effect that potent inhibition hepatitis B virus DNA (deoxyribonucleic acid) (HBV DNA) is duplicated.
Table 2 sample in the time of the 8th day to the suppression ratio of the HBV dna replication dna of HepG2.2.15 cell
This embodiment presentation of results: the flavanolignan's chemical compound shown in the formula (1) has more intense inhibitory action to duplicating of hepatitis B virus DNA (deoxyribonucleic acid) (HBV DNA), and it suppresses activity to duplicating of HBV DNA and still surpasses 59% than low dosage (20 mcg/ml) time.And the positive control alpha-interferon only has 38.2% inhibition activity to HBV DNA the 8th day test concentrations the highest when (10000 units per ml), therefore this chemical compound belongs to significantly effectively non-nucleoside inhibition hepatitis B virus natural product, be worth further paying close attention to and further investigation, and can expect that further optimized development is for suppressing the medicine of HBV dna replication dna.
When above-mentioned description elaboration was of the present invention, the purpose that embodiment is provided simultaneously was to illustrate actual mechanical process of the present invention and meaning of the present invention.In the time of in entering claim of the present invention and its equivalent scope, practical application of the present invention comprises all general variations, cooperates, or improves.
Claims (3)
1. has the methyl substituted silybin ester of ethoxycarbonyl on the A ring of structure shown in the formula (1)
Flavonolignan or its officinal salt are used for the purposes of preparation treatment hepatitis B medicine;
The name of formula (1) chemical compound is called: (±)-2,3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5 ,-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
2. have on the A ring of structure shown in the formula (1) the methyl substituted silybin ester flavonolignan of ethoxycarbonyl or its officinal salt and be used for the purposes that preparation reduces hepatitis B virus surface antigen HBsAg medicine
The name of formula (1) chemical compound is called: (±)-2,3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5 ,-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
3. have on the A ring of structure shown in the formula (1) the methyl substituted silybin ester flavonolignan of ethoxycarbonyl or its officinal salt and be used for the purposes that preparation suppresses hepatitis B virus DNA (deoxyribonucleic acid) HBV dna replication dna medicine;
The name of formula (1) chemical compound is called: (±)-2,3-dihydro-2-[2,3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-2-methylol-1,4-benzodioxane-6-]-7-(ethoxycarbonyl ylmethoxy)-3,5 ,-dihydroxy-4H-1-.alpha.-5:6-benzopyran-4-ketone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101817219A CN101829101B (en) | 2010-05-25 | 2010-05-25 | Application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101817219A CN101829101B (en) | 2010-05-25 | 2010-05-25 | Application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101829101A true CN101829101A (en) | 2010-09-15 |
| CN101829101B CN101829101B (en) | 2012-05-23 |
Family
ID=42713424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101817219A Expired - Fee Related CN101829101B (en) | 2010-05-25 | 2010-05-25 | Application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101829101B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1990484A (en) * | 2005-12-26 | 2007-07-04 | 浙江海正天华新药研发有限公司 | Silybin esters derivatives and preparation and use thereof |
| CN101104616A (en) * | 2006-07-14 | 2008-01-16 | 浙江大学 | Dehydrosilibinin diester derivatives, preparation method and use thereof |
| CN101613346A (en) * | 2009-06-04 | 2009-12-30 | 大理学院 | The preparation method of the nuclear substituted silybin ether of A and medicinal use thereof |
-
2010
- 2010-05-25 CN CN2010101817219A patent/CN101829101B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1990484A (en) * | 2005-12-26 | 2007-07-04 | 浙江海正天华新药研发有限公司 | Silybin esters derivatives and preparation and use thereof |
| CN101104616A (en) * | 2006-07-14 | 2008-01-16 | 浙江大学 | Dehydrosilibinin diester derivatives, preparation method and use thereof |
| CN101613346A (en) * | 2009-06-04 | 2009-12-30 | 大理学院 | The preparation method of the nuclear substituted silybin ether of A and medicinal use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《江苏医药杂志》 20000630 刘燕等 "水飞蓟素治疗慢性乙型肝炎疗效观察" 第445－446页 1-3 第26卷, 第6期 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101829101B (en) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101829087A (en) | Application of p-bromo-cinnamyl silybin in preparing medicament for treating viral hepatitis B | |
| CN101829091B (en) | Use of acetamide dehydrogenation silibinin as medicament for treating viral hepatitis B | |
| CN101829086B (en) | Application of aromatic carbamoyl dehydro-silibinin as medicament for treating viral hepatitis B | |
| CN101829090B (en) | Application of diamine formyl dehydrogenated silybin serving as medicament for curing viral hepatitis B | |
| CN101829094B (en) | Application of ring E bromine substituted silybin in preparing medicaments for treating viral hepatitis B | |
| CN101955478B (en) | Preparation of brominated flavanonollignan and application in medicine for treating viral hepatitis B | |
| CN101829083B (en) | Application of substituted silybin ester in preparing medicament for treating virus hepatitis B | |
| CN101829096B (en) | Application of ring E iodine substituted silybin in preparing medicaments for treating viral hepatitis B | |
| CN101829095B (en) | Use of lignanoid containing benzyloxy flavones in preparation of drugs for treating viral hepatitis B | |
| CN101919840A (en) | Application of B/E ring substituted silybin for preparing medicament for treating virus hepatitis B | |
| CN101829100B (en) | Application of flavanonol lignanoid in preparing antiviral hepatitis B medicine | |
| CN101829104B (en) | Application of ring A coupling flavonolignan in preparing medicaments for treating viral hepatitis B | |
| CN101829101B (en) | Application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B | |
| CN101829103A (en) | Application of flavonoid quercetin dimmer as medicament for treating viral hepatitis B | |
| CN101912385B (en) | Application of dimethyl dehydrated silybin in preparing medicaments for treating virus hepatitis B | |
| CN101953826B (en) | Application of flavanolignan to preparation of medicament for treating viral hepatitis B | |
| CN101822666A (en) | Application of benzoyl silibinin for preparing medicaments for treating viral hepatitis B | |
| CN101829084A (en) | Application of aminobenzoyl silybin for preparing virus hepatitis B medicine | |
| CN101912383B (en) | Application of E-ring demethoxy-silibinin for preparing medicament for treating viral hepatitis B | |
| CN101829098B (en) | Application of substituted isosilybin in preparing medicament for treating virus hepatitis B | |
| CN101829088B (en) | Application of B/E bi-methoxy silybin in preparing medicaments for treating viral hepatitis B | |
| CN101953827B (en) | Application of flavone lignan (+/-) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B | |
| CN101829085B (en) | Application of ring A dioxane flavonolignan in preparing medicaments for resisting hepatitis B viruses (HBV) | |
| CN101829106B (en) | Application of diallyl propyl flavonolignan in preparation of medicament for curing hepatitis B | |
| CN101829099A (en) | Application of 4-cinnamoyl chloride silybin in preparing medicaments for treating viral hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20140525 |